SciBase Partners with Castle Biosciences for Clinical Study in Dermatology Innovations

SciBase Partners with Castle Biosciences for Clinical Study

In a significant development in the field of dermatological care, SciBase Holding AB, renowned for its cutting-edge AI-driven devices, has announced an initial order from Castle Biosciences as part of their recent collaboration. This pivotal order includes Nevisense Go and corresponding electrodes, valued at approximately $0.8 million (around 8 million SEK). The collaborative efforts aim to enhance therapeutic solutions for patients dealing with atopic dermatitis (AD).

On June 16, 2025, SciBase entered into a strategic partnership and licensing agreement with Castle Biosciences, recognized as a leading entity in molecular diagnostics. The primary goal of this collaboration is to create an advanced diagnostic test specifically designed to forecast and manage flare-ups in atopic dermatitis patients. The initial product order will be utilized in a clinical study for this groundbreaking project, with shipments set to commence in the fourth quarter of this year.

Pia Renaudin, the CEO of SciBase, expressed enthusiasm regarding the partnership: "The collaboration with Castle Biosciences is moving forward at a fast pace, and this first order signals the initiation of our first joint study. At SciBase, we are excited to work alongside Castle Biosciences to provide patients with skin barrier dysfunctions better access to effective therapies."

Castle Biosciences has also made a significant financial commitment to SciBase, becoming its second-largest shareholder following the signing of the collaboration agreement. This investment underscores their trust in SciBase's innovative potential and the anticipated success of their joint endeavors in dermatology.

SciBase is widely acknowledged as a leader in utilizing artificial intelligence for early detection and prevention strategies in dermatology. The firm has developed a distinctive point-of-care platform known as Nevisense, which integrates AI technologies with advanced electrical impedance spectroscopy (EIS) to significantly improve diagnostic accuracy. The overarching aim of SciBase is to alleviate patient suffering and enable healthcare providers to deliver timely interventions, thereby enhancing life quality and reducing healthcare expenses.

Founded on two decades of research conducted at the renowned Karolinska Institute in Stockholm, Sweden, SciBase has solidified its reputation for driving advancements in skin health management. Since its public listing on the Nasdaq First North Growth Market on June 2, 2015, the company has continued to innovate and expand its contributions to the healthcare sector.

For those interested in further information, the company provides access to press releases and financial reports through their investor portal at SciBase Investor Relations.

This collaboration could pave the way for significant advancements in the treatment of atopic dermatitis, potentially setting new standards in patient care. Organizations like SciBase and Castle Biosciences are at the forefront of leveraging technology to enhance healthcare outcomes, promising a future filled with potential solutions for patients suffering from chronic skin conditions.